EUDA Secures Distribution Rights for T-Cell Immunotherapy in Malaysia at $8,000 Per Treatment
核心洞察
EUDA Health Holdings Limited (搜索) has secured distribution rights for T-cell (搜索) immunotherapies in Malaysia from Shenzhen Inno Immune Co. Ltd. (搜索), marking its second major cell therapy expansion in 2025.
The T-cell immunotherapy (搜索) package will retail at USD 8,000 per treatment, representing a significant cost reduction compared to traditional pricing in regional markets.
This partnership follows EUDA's April 2025 distribution agreement with Guangdong Cell Biotech Co., Ltd. (搜索), reflecting the company's strategic push into regenerative and longevity medicine.
EUDA Health Holdings Limited (搜索) (NASDAQ: EUDA) announced it has secured distribution rights for T-cell (搜索) immunotherapies in Malaysia developed by Shenzhen Inno Immune Co. Ltd. (搜索), a Chinese developer of autologous cellular therapeutic (搜索) and customized medicines. The therapies are designed to restore and rebuild the body's natural defenses against a wide range of diseases.
Strategic Expansion into Cell Therapy
This partnership represents EUDA's second major advancement into cell therapy in 2025, following its April distribution agreement with Guangdong Cell Biotech Co., Ltd. (搜索), a leader in autologous stem cell therapies in China. The combined initiatives reflect EUDA's accelerated expansion into regenerative and longevity medicine, reinforcing its commitment to deliver science-driven, non-invasive solutions for aging (搜索) and chronic conditions (搜索).
Under the agreement terms, Guangdong Key Lock Health Management Co., Ltd. (搜索) (Keylock), a strategic partner to both Shenzhen Inno and EUDA, has granted CK Health Plus Sdn Bhd (搜索), EUDA's wholly-owned subsidiary, the right to market and sell T-cell (搜索) immunotherapies to EUDA customers in Malaysia.
Accessible Pricing Strategy
The T-cell immunotherapy (搜索) package will retail at USD 8,000 per treatment, which EUDA describes as "a fraction of the traditional cost in other markets in the region." This pricing strategy reflects a clinically advanced, personalized approach to long-term immune system support while addressing historical cost barriers that have limited access to such treatments across Malaysia.
Scientific and Institutional Backing
Shenzhen Inno brings substantial credentials to the partnership, including a GMP-standard cell and virus preparation center ensuring pharmaceutical-grade quality. The company has received recognition under China's prestigious "Peacock Plan" project for elite innovation teams and secured strategic backing from venture capital firm Sequoia Capital (搜索) during its angel investment round. Additionally, Shenzhen Inno has established a Postdoctoral Innovation Practice Base to foster high-level talent development.
Market Positioning and Growth Potential
Alfred Lim, CEO of EUDA, stated: "This strategic expansion into T-cell immunotherapy (搜索) represents a pivotal moment for EUDA as we continue to diversify our healthcare portfolio and deliver innovative solutions to our customers. By working with Shenzhen Inno and Keylock, we're offering world-class immune-enhancing therapies to Malaysians at a fraction of traditional costs, furthering our mission to transform the health and wellness landscape in the region, creating significant growth potential going forward."
EUDA positions itself as a Singapore-based leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China. The company aims to address the evolving healthcare needs of over 1.8 billion people across a region experiencing significant demographic shifts, with more than 30% of the population aging (搜索) rapidly. EUDA's strategy centers on transforming regional healthcare from reactive medical treatment to proactive, longevity-focused care.